AxoGen (AXGN) is a medical technology company dedicated to peripheral nerve repair.
AXGN's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.
In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
AXGN provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally.
AxoGen, Inc. is headquartered in Alachua, Florida.
April 23, 2024
RegMed Investors (RMi) Closing Bell: welcoming the upside trend
April 23, 2024
RegMed Investors’ (RMi) pre-open: finding our way
April 22, 2024
RegMed Investors (RMi) Closing Bell: a flash sector relief rally?
April 22, 2024
RegMed Investors’ (RMi) pre-open: questionable timing
April 11, 2024
RegMed Investors (RMi) Closing Bell: sector seeps, although with subdued selling
April 10, 2024
RegMed Investors (RMi) Closing Bell: the cell and gene therapy sector got chewed-up, bloods everywhere
April 5, 2024
RegMed Investors (RMi) Closing Bell: economic circumstances drove a 5 session/weekly downside
April 4, 2024
RegMed Investors (RMi) Closing Bell: economics undermine sector’s share pricing before jobs report
April 3, 2024
RegMed Investors (RMi) Closing Bell: The switch is still flipped
35 companies, 1 interpreter!
Insight, foresight and recommendation
AxoGen, Inc. (AXGN) – January '18 opened at $27.95 with an upside of $28.05 on 2/1 while dropping to $27.40 on 2/16 ... since November of '17 appreciation has withstood mild drags to the downside ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors